Filenews 20 September 2021
Moderna's vaccine appears to be the most effective in preventing severe Covid-19 and hospitalization due to it, according to comparative analysis of data from the U.S. Centres for Disease Control and Prevention (CDC), but the Pfizer/BioNTech vaccine does not fall far short.
Both mRNA vaccines of the two doses, which have a similar composition, are better seen in reducing the risk of hospitalization after coronavirus infection, compared to the single-dose vaccine of the Johnson & Johnson.
Moderna's vaccine reduces the risk of hospitalization or severe Covid-19 disease by 93% after two weeks after the second dose, while protection remains above 90% for at least four months after full vaccination.
The Pfizer-BioNTech vaccine provides 88% protection for the fully vaccinated, which is reduced to 77% four months after the second dose. The Johnson & Johnson reduces the risk of hospitalization by 71%, "showing somewhat lower efficacy," according to CDC researchers.
The above findings are based on the evaluation of the level of antibodies in approximately 4,500 fully vaccinated adults and the comparison of hospitalization rates with approximately 2,400 unvaccinated, during the period March - August 2021, therefore they also include the effects of the more contagious variant of the Coronavirus Delta. A related publication was made in the CDC's weekly "Morbidity and Mortality Weekly Report (MMWR)".
Last week CDC data had shown that the fully vaccinated have at least ten times less risk of hospitalization and death due to coronavirus, compared to unvaccinated people. In any case, cdc scientists stressed that "all approved or licensed vaccines by the FDA provide significant protection against Hospitalization due to Covid-19."
